2026-2032 年婴幼儿营养低聚醣市场规模（按形式、应用、类型和地区）

婴儿营养寡糖市场评估（2026-2032）

越来越多的家长开始青睐机能性食品不仅能提供基本营养，还能带来其他健康益处。添加寡糖的婴儿奶粉完美契合了这一新兴趋势，为婴儿提供了量身定制的机能性食品选择。因此，随着机能性食品的普及，其市场规模预计将在2024年超过2.3565亿美元，到2032年将达到4.0785亿美元。

婴儿奶粉製造商正逐步在其产品中加入寡醣，以模拟母乳的健康益处并提高奶粉的营养成分。这种新兴模式满足了那些希望用最接近母乳的替代品餵养婴儿的父母的需求。因此，低聚醣在产品中的高渗透率将推动市场在2026年至2032年间以10.2%的复合年增长率成长。

婴儿营养市场中的寡糖：定义/概述

寡糖是小分子碳水化合物，与淀粉等复合碳水化合物相比分子长度较短。寡糖是母乳中含量第三丰富的固态成分，仅次于脂肪和乳糖。寡糖是有益菌的重要食物来源，有助于培养婴儿健康的肠道菌丛。越来越多的製造商将寡糖添加到其产品中，以复製母乳中的健康益处。其他寡糖包括人乳寡糖、三糖和半乳寡糖。

母乳寡糖可增加母乳哺育婴儿大肠桿菌群中双歧桿菌的数量。这种增加，加上潜在有害细菌数量的显着减少，都归因于寡糖的双歧桿菌促生特性。母乳低聚醣不仅有助于母乳哺育婴儿的肠道菌群，现在还能有效抑制细菌黏附在上皮表面。

未来，我们或许会发展出更接近母乳的新一代寡糖。随着未来寡糖生产过程的日益精进，它们将更具成本效益，也更容易取得。婴儿奶粉将根据每个婴儿的特定需求，结合遗传、肠道菌丛组成和过敏风险等因素，以客製化特殊的寡糖配方。

寡糖的多功能性如何推动其在婴儿营养市场的成长？

寡糖的结构多样性、丰富性和多功能性推动了婴儿营养领域对寡糖的需求。寡糖是天然存在于母乳中的多功能聚醣。寡糖作为益生元，滋养肠道中的有益菌。寡糖作为有益菌的支持作用能够促进肠道菌丛的和谐平衡，这对于高效消化和增强免疫功能至关重要。寡糖为有益菌提供了良好的环境，有助于肠道健康，并带来多方面的益处，远不止于消化功能。

寡糖作为益生元，促进肠道有益菌的生长，增强免疫系统。透过增强免疫系统，寡糖可以减少疾病，改善整体健康。寡糖可以减少过敏，在小鼠怀孕期间饲餵某些不可消化的寡糖，可以减轻其后代的过敏性气喘症状。

三糖与其他碳水化合物一样，在体内分解成葡萄糖，葡萄糖是细胞能量的主要来源。三醣与单醣等单醣不同，它们的消化速度略慢，因此能量释放更缓慢、更持续。不同的三糖在体内发挥不同的作用。例如，麦芽三糖是葡萄糖的三糖之一，它有助于肝醣储存，这是人体在需要时储存和释放能量的机制。

双醣是人体容易取得的能源来源。摄取后，它们会被消化酵素分解成单醣成分，这些单醣成分很容易在小肠中吸收，并分布到全身各处的细胞。这种快速吸收能够快速提供能量，支持各种身体功能。

家长意识的缺乏究竟阻碍了寡糖在婴儿营养市场的成长吗？

儘管目前已有研究，但某些寡糖对新生儿健康的长期影响尚不清楚。由于缺乏确凿的长期数据，某些医疗保健提供者和家长可能不愿意采用这些配方奶粉。并非所有家长都了解婴儿奶粉中添加寡醣的益处。这种缺乏了解的情况，加上对某些化学物质的潜在误解，可能会阻碍这些配方奶粉获得广泛的市场认可。

监管机构对婴儿奶粉中可添加的寡糖种类和允许含量製定了标准。虽然严格的监管对于确保安全性和有效性至关重要，但它们可能会无意中扼杀创新和新型寡糖的市场推广。因此，这种法律规范在确保产品安全和促进婴儿营养进步之间难以取得平衡。

从婴儿奶粉转换为含寡糖配方奶粉的婴儿可能会出现消化器官系统不适，例如腹胀和胀气，尤其是在过渡不循序渐进的情况下。这一过渡期凸显了谨慎引入强化寡糖配方奶粉的重要性，以避免潜在的不适。

配方奶粉中添加的寡糖虽然有用，但其结构与母乳中天然存在的寡糖不同。这种结构差异可能会导致一些人质疑配方奶粉和母乳的整体等效性。虽然添加寡糖可以改善配方奶粉的营养成分，但为了维护消费者的信心，识别并纠正这些可察觉的差异至关重要。

目录

第一章 婴幼儿营养寡糖全球市场介绍

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

4. 婴幼儿营养寡糖的全球市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球婴幼儿营养寡糖市场（依型态）

• 概述
• 粉末
• 液体

6. 全球婴幼儿营养寡糖市场（依应用）

• 概述
• 食物
• 健康食品
• 饮料
• 製药

7. 全球婴幼儿营养低聚醣市场（按类型）

• 概述
• 半乳寡糖
• 母乳寡糖
• 果寡糖

8. 全球婴幼儿营养低聚醣市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东

9. 全球婴幼儿营养寡醣市场竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第十章 公司简介

• Nissin Sugar Co. Ltd.
• Yakult Pharmaceutical Industry Co., Ltd.
• Kerry Group plc
• Taiwan Fructose
• Dupont nutrition & health
• Royal FrieslandCampina NV
• Abbot
• Ingredion
• Biosynth Carbosynth.
• Dextra Laboratories Ltd.
• Inbiose NV
• Jennewein Biotechnologie GmbH
• Tereos
• Zuchem

第十章 附录

• 相关调查

Oligosaccharides in Infant Nutrition Market Valuation - 2026-2032

The growing inclination among parents towards functional foods, which go beyond providing basic nutrition by offering additional health benefits. Infant formula enriched with oligosaccharides perfectly fits into this emerging trend, presenting a functional food choice tailored specifically for infants. Thus, the increasing adoption of functional foods is driving market size to surpass USD 235.65 Million in 2024 to reach the valuation of USD 407.85 Million by 2032.

Manufacturers of infant formula are progressively integrating oligosaccharides into their products to emulate the health advantages of breast milk and elevate the nutritional content of their formulas. This emerging pattern addresses the needs of parents who aspire to offer their infants the most analogous substitute to breast milk available. Thus, the high enactment of oligosaccharides in products is enabling the market to grow at a CAGR of 10.2% from 2026 to 2032.

Oligosaccharide in Infant Nutrition Market: Definition/ Overview

Oligosaccharides are small carbohydrate molecules, shorter in length compared to complex carbohydrates such as starches. Oligosaccharides rank as the third most prevalent solid component in breast milk, following fats and lactose. They act as a vital food source for beneficial bacteria, fostering a healthy gut microbiome in infants. Manufacturers are increasingly incorporating oligosaccharides into their products to replicate the health advantages found in breast milk. In addition, there are types of oligosaccharides human milk oligosaccharide, trisaccharide, and Galactooligosaccharides.

The human milk oligosaccharides lead to a rise in the population of bifidobacteria in the colonic flora of breastfed infants. This increase is coupled with a notable decrease in the number of potentially harmful bacteria, attributed to the bifidogenic properties of oligosaccharides. Human milk oligosaccharides not only contribute to intestinal flora in breastfed infants but now oligosaccharides also serve as a potent inhibitor of bacterial adhesion to epithelial surfaces.

In the future, it is likely to develop a new generation of oligosaccharides that closely resemble breast milk. The advanced production of oligosaccharide in the future can make it cost-effective, and increase its accessibility. The emergence of personalized infant formula featuring specific blends of oligosaccharides tailored to individual baby's requirements, taking into account factors such as genetics, gut microbiome composition, and potential allergies.

How the Multifunctionality of Oligosaccharide is Driving the Growth of Oligosaccharide in the Infant Nutrition Market?

The structural diversity, quantity, and multifunctionality of oligosaccharides are driving the demand for oligosaccharides in human infant nutrition. Oligosaccharide is a prominent component in human milk it is a multifunctional glycan, which is naturally present in human milk. Oligosaccharides serve as prebiotics, which nourish the beneficial bacteria residing in the gut. This support of oligosaccharide support as a good bacteria fosters a harmonious balance within the gut microbiome, it is vital for efficient digestion and bolstered immune function. Oligosaccharides provide a favorable environment for beneficial microorganisms, they also contribute to gut health, offer multifaceted benefits, and extend beyond digestion.

Oligosaccharide promote the growth of beneficial gut bacteria, because of its prebiotic action and fortifies the immune system. Oligosaccharides reduce illness by bolstering the immune system and demonstrate to improve general health and well-being. Oligosaccharide reduces the allergy, during pregnancy in mice the specific nondigestible oligosaccharide led to reduced allergic asthma symptoms in the offspring.

Trisaccharides, akin to other carbohydrates, undergo breakdown into glucose within the body, serving as the primary fuel source for cellular energy. Trisaccharides, distinguished from simple sugars like monosaccharides, undergo digestion at a slightly slower pace, resulting in a more gradual and sustained release of energy. Specific trisaccharides fulfill distinct roles within the body. For instance, maltotriose, a glucose trisaccharide, contributes to glycogen storage, which constitutes the body's mechanism for storing and releasing energy as needed.

Disaccharides serve as an easily accessible energy source for the body. Upon ingestion, digestive enzymes break them down into their monosaccharide components, which are readily absorbed by the small intestine and distributed to cells throughout the body. This rapid absorption facilitates quick energy delivery to support a range of bodily functions.

How the Lack of Awareness among the Parents is Hampering the Growth of Oligosaccharides in the Infant Nutrition Market?

Despite current studies, the long-term effects of particular oligosaccharides on newborn health are not well understood. Certain healthcare providers or parents may be hesitant to adopt these formulae due to a lack of conclusive long-term data. Not all parents are aware of the benefits of oligosaccharides in infant formula. This lack of understanding, along with potential misconceptions about certain chemicals, could be a barrier to widespread market acceptance.

Regulatory bodies have created criteria for the permitted types and quantities of oligosaccharides in infant formula. While tight regulations are necessary to ensure safety and efficacy requirements, they can unintentionally stifle innovation and the introduction of novel oligosaccharides to the market. As a result, this regulatory framework strikes a difficult balance between guaranteeing product safety and promoting advances in baby nutrition.

Infants switching to oligosaccharide-containing formula may experience digestive discomfort such as bloating or gas, especially if the transition is not gradual. This transition period emphasizes the significance of introducing oligosaccharide-enriched formulas with caution to avoid potential discomfort.

Although helpful, oligosaccharides added to the formula differ structurally from those found naturally in breast milk. This structural distinction may lead some to question the overall equivalence of formula and breast milk. While oligosaccharide supplementation improves the formula nutritionally, it is critical to identify and rectify any perceived discrepancies to maintain customer trust.

Category-Wise Acumens

How the Increasing Consumer Awareness of Gut Health and the Rise in the Infant Population is Driving the Human Milk Oligosaccharide Segment Growth?

The human milk oligosaccharide segment is substantially growing in the oligosaccharide infant nutrition market and is expected to continue its growth throughout the forecast period. Rising consumer knowledge of the benefits of gut health, as well as increased demand for nutritional supplements, are important drivers driving the human milk oligosaccharide (HMO)) segment in the oligosaccharide infant nutrition market. HMOs, known for their antibacterial and prebiotic qualities, are set to become widespread in a variety of industries, including infant formulae, pharmaceuticals, and functional foods. Population growth, rising mortality rates, and a greater emphasis on health awareness are likely to drive the HMO business ahead.

In addition, the rise in the infant population is contributing to the growth of the human milk oligosaccharide segment. For instance, the current birth rate in 2024 is 17.299 births per 1000 people and 17.464 per 1000 people in 2023. The increasing birth rate is fueling the demand for human milk oligosaccharides. In the United States, the provisional number of births is 3,661,220 in 2022.

The rising prevalence of chronic illnesses such as gastrointestinal disorders, diabetes, high blood pressure, and rickets is driving up demand for functional foods and beverages, boosting growth in the human milk oligosaccharide market. In addition, the infant formula and baby food businesses are expected to grow significantly because of rising demand, increased HMO production, and regulatory approvals. Ongoing research is always revealing new health benefits related to certain HMO configurations. This ongoing research is expected to widen the potential applications of HMOs beyond newborn nutrition, accelerating market growth.

How the Health Benefits Associated with the Oligosaccharide is Fueling the Growth of the Food Segment in the Oligosaccharide in Infant Nutrition Market?

The food segment is significantly showing the growth in the oligosaccharide in the infant nutrition market. The wide range of health advantages associated with functional oligosaccharides is a major reason for their integration into dietary products. These advantages include immunological modulation, intestinal health promotion, enhanced stomach microbial activity, increased calcium absorption, and bone mineral density maintenance, particularly among adolescents.

Furthermore, functional oligosaccharides provide distinct physiological benefits such as being zero or low in calories while performing specific functions such as stimulating the proliferation of beneficial bacteria such as Bifidobacterium, enhancing the body's immune response, preventing dental caries and constipation, and even exhibiting potential anti-tumor properties.

Natural sources of oligosaccharides, such as fructooligosaccharides (FOS) found in fruits and vegetables like onions and bananas, provide an extra impetus for their use in food items. Although these natural oligosaccharides may be difficult for the human body to digest, they are valuable bioactive components that helpful bacteria such as Bifidobacterium can easily consume. This usage promotes a healthy and active gut microbiota, which protects against gastrointestinal illnesses.

How will the Rising Birth Rate in Asia Pacific Drive the Market?

Asia Pacific is substantially growing the oligosaccharide in the infant nutrition market thanks to the increasing awareness of the importance of early childhood nutrition, combined with a comprehension of the favorable function oligosaccharides play in newborn health. As parents grow more health-conscious, they are actively looking for infant feeding solutions that not only meet their fundamental nutritional requirements but also provide additional health benefits.

In response to this trend, there is a shift toward a more holistic approach to infant nutrition, in which parents prioritize products that provide comprehensive nutritional support, such as oligosaccharides, which promote overall health and well-being. This increased understanding emphasizes the significance of early nutritional changes in determining long-term health outcomes for infants.

The growing demand for functional foods in APAC reflects a larger trend toward preventative healthcare and wellness-oriented lifestyles. Parents are looking for child nutrition products that contain oligosaccharides, which they believe are important for immunological health, digestive function, and overall growth and development during infancy.

Healthcare professionals, government organizations, and industry stakeholders use educational campaigns and initiatives to raise awareness about the importance of early childhood nutrition and the benefits of oligosaccharides. By providing parents with knowledge and information, these initiatives help to meet the growing demand for oligosaccharide-enriched infant feeding products in the APAC market.

Competitive Landscape

The competitive landscape for oligosaccharides in infant nutrition is dynamic and evolving. Companies that can successfully navigate these trends through innovation, cost-effectiveness, strategic partnerships, and a focus on sustainability are likely to thrive in this growing market.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players

operating in the oligosaccharides in infant nutrition market include:

• Nissin Sugar Co. Ltd.
• Yakult Pharmaceutical Industry Co., Ltd.
• Kerry Group plc
• Taiwan Fructose
• Dupont nutrition & health
• Royal FrieslandCampina N.V.
• Abbot
• Ingredion
• Biosynth Carbosynth.
• Dextra Laboratories Ltd.
• Inbiose NV
• Jennewein Biotechnologie GmbH
• Tereos
• Zuchem

Key Devlopments

• In February 2019, DuPont Nutrition and Health announced an agreement with Lonza Specialty to manufacture and supply the CARE 4U-FL a Human Milk Oligosaccharide.
• In October 2023, Royal FrieslandCampina N.V. announced its entrance into the world's largest infant milk formula market in China.

Oligosaccharide in Infant Nutrition Market, By Category

• Form:
• Powder
• Liquid
• Application:
• Food
• Health Products
• Drinks
• Medicine
• Type:
• Galactooligosaccharides
• Human Milk Oligosaccharides
• Fructooligosaccharides
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL OLIGOSACCHARIDES IN INFANT NUTRITION MARKET,

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL OLIGOSACCHARIDES IN INFANT NUTRITION MARKET, OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL OLIGOSACCHARIDES IN INFANT NUTRITION MARKET, BY FORM

• 5.1 Overview
• 5.2 Powder
• 5.3 Liquid

6 GLOBAL OLIGOSACCHARIDES IN INFANT NUTRITION MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Food
• 6.3 Health Products
• 6.4 Drinks
• 6.5 Medicine

7 GLOBAL OLIGOSACCHARIDES IN INFANT NUTRITION MARKET, BY TYPE

• 7.1 Overview
• 7.2 Galactooligosaccharides
• 7.3 Human Milk Oligosaccharides
• 7.4 Fructooligosaccharides

8 GLOBAL OLIGOSACCHARIDES IN INFANT NUTRITION MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East

9 GLOBAL OLIGOSACCHARIDES IN INFANT NUTRITION MARKET, BY COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Nissin Sugar Co. Ltd.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Yakult Pharmaceutical Industry Co., Ltd.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Kerry Group plc
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Taiwan Fructose
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Dupont nutrition & health
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Royal FrieslandCampina N.V.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Abbot
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Ingredion
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Biosynth Carbosynth.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Dextra Laboratories Ltd.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments
• 10.11 Inbiose NV
  • 10.11.1 Overview
  • 10.11.2 Financial Performance
  • 10.11.3 Product Outlook
  • 10.11.4 Key Developments
• 10.12 Jennewein Biotechnologie GmbH
  • 10.12.1 Overview
  • 10.12.2 Financial Performance
  • 10.12.3 Product Outlook
  • 10.12.4 Key Developments
• 10.13 Tereos
  • 10.13.1 Overview
  • 10.13.2 Financial Performance
  • 10.13.3 Product Outlook
  • 10.13.4 Key Developments
• 10.14 Zuchem
  • 10.14.1 Overview
  • 10.14.2 Financial Performance
  • 10.14.3 Product Outlook
  • 10.14.4 Key Developments

10 Appendix

• 10.1 Related Research